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Abstract 
With more advanced and more aggressive chemotherapy cancer treatment leading 
to higher survival rates, complications with quality of life are becoming more prominent. 
Of these complications, delayed cognitive processing, commonly known as “chemo 
brain,” is becoming a topic of interest. Cognitive changes are some of the most common 
as well as most challenging complications associated with central nervous system (CNS) 
directed treatment, such as intrathecal chemotherapy, for acute lymphoblastic leukemia 
(ALL) and brain tumors. The term “chemo brain” is often used to describe self-reported 
or observed cognitive processing delays in patients who receive chemotherapy as a form 
of cancer treatment  (Raffa, 2009). Although these cognitive delays have the potential to 
be serious side effects, little education is given to the patients and families regarding 
these possibilities prior to the initiation of cancer treatment. The purpose of this paper is 
three fold: 1) to define and discuss the etiology of “chemo brain,” 2) discuss the best 
assessment and evaluation of severity of “chemo brain,” and 3) to explore pediatric 
oncology nurses reports of practice implications for teaching and supporting pediatric 
patients and their families experiencing “chemo brain.” A theoretical framework that will 
guide the research is Erikson’s Theory of Psychosocial Development with a focus on the 
school age stage of industry versus inferiority. With the possible gap in knowledge and 
skill that may be present in these children who have undergone chemotherapy, there is a 
significantly higher chance of them developing a sense of inferiority rather than the 
preferred sense of industry. Convenience and snowball sampling will be used to locate 
pediatric oncology registered nurses to complete the research instrument. This pilot study 
has a qualitative/descriptive design with a goal of 30 subjects. Research data will be 
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collected through a short survey created by the primary investigator that has construct 
and content validity from two advanced practice pediatric oncology nurses.  
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Introduction 
 With more advanced and more aggressive chemotherapy cancer treatment leading 
to higher survival rates, complications with quality of life are becoming more prominent, 
especially delayed cognitive processing, commonly known as “chemo brain.” At 
diagnosis and throughout treatment, patients and families are routinely educated about the 
plan of care, but according to oncology nurses’ reports, too often details regarding the 
possibility of cognitive declines or deficits are left out.  
Background 
 Cognitive changes are some of the most common as well as challenging 
complications associated with central nervous system (CNS) directed treatment, such as 
intrathecal chemotherapy, for acute lymphoblastic leukemia (ALL) and brain tumors. The 
estimated incidence of patients who experience deficits in cognitive processing related to 
their CNS directed treatment is approximately 20% to 40% for children with ALL and 
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40% to 100% for children with brain tumors (Moore et al., 2013). The term “chemo 
brain” is often used to describe self-reported or observed cognitive processing delays in 
patients who receive chemotherapy as a form of cancer treatment  (Raffa, 2009). The 
clinical manifestations of “chemo brain” can “affect multitasking, create stress, and 
weaken performance when patients are challenged by high-level cognitive demands” 
(Staat & Segatore, 2005).  
Purpose 
 The purpose of this paper is three fold: 1) to define and discuss the etiology of 
“chemo brain,” 2) discuss the best assessment and evaluation of severity of “chemo 
brain,” and 3) to explore pediatric oncology nurses reports of practice implications for 




 “Chemo Brain” (CB) is a term used to describe the general cognitive deficit that 
results from cancer chemotherapy treatment. According the Evens & Eschiti (2009), CB 
can be simply described as “dysfunction, weakening, or impairment” of the memory in 
patients who have undergone chemotherapy treatment for cancer. Raffa et al. (2006) 
suggested that these impairments can be self-reported or observed. A more specific 
definition of CB stated that it presents as “weakened cognitive abilities, speed of 
information processing or reaction time, and organizational skills” along with the 
negative impact on “language ability, memory, concentration, and attention” (Staat & 
Segatore, 2005). Many of these core symptoms have been termed “executive functions,” 
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mainly including the “ability to allocate attentional resources and to plan and organize 
behavior” (Mulhern & Palmer, 2003). Although theses deficits may seem to cause 
deteriorating effects, it is suggested that “young children aren’t actually dementing, but 
rather are not acquiring new information and skills at an appropriate age” (Duffner, 2009) 
 According to Staat & Segatore (2005), the patient’s quality of life may be 
significantly affected because of the severity of the CB symptoms. Cognitive deficits may 
be subtle enough so only the patient and close relatives notice, but they also may be 
severe enough to cause others to notice – which is noted to be most difficult for the 
patient as well as their family and close friends.  
   Moore et al. (2013) and Evens & Eschiti (2009) both presented the statistic that 
as many as 40% of pediatric acute lymphoblastic leukemia (ALL) patients who are 
treated with chemotherapy alone will report CB. Overall, studies have shown that 
cognitive difficulties affect 25%-35% of all patients that undergo systemic chemotherapy 
(Evens & Eschiti, 2009).  
 Deficits of CB often appear over time rather than right away. In fact, myelination 
changes in the central nervous system (CNS) from a chemotherapy drug, 5-fluorouracil 
can be delayed for several months and may become progressive (Evens & Eschiti, 2009). 
By the late 1990’s, reports began to suggest that children who were treated for ALL 
without cranial radiation therapy but with chemotherapy developed progressive cognitive 
declines 3-4 years following the completion of their chemotherapy (Duffner, 2009). More 
detrimental, it has been suggested that in a small minority of patients, CB is still 
perceptible 10 years after the completion of treatment (Staat & Segatore, 2005).  
Etiology of “Chemo Brain” 
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 The deficits of CB are believed to occur because of alterations in the blood-brain 
barrier (BBB), vascular injury, and myelination changes. With this BBB impairment, 
toxic agents are allowed access to the brain more readily and in normal circumstances 
where entry would not usually happen (Evens & Eschiti, 2009). In addition to these 
abnormalities, Mulhern & Palmer (2003) suggested that the late effects might also 
include diffuse and multifocal white matter abnormalities, microvascular occlusion, and 
calcifications. While Raffa (2009) stated that mainly white matter abnormalities were 
related to chemotherapy treatment, Evens & Eschiti (2009) discussed how researchers 
have also shown a decrease in the brain’s grey matter along with the demyelination of 
white matter fibers following chemotherapy treatment. In neuroimaging studies discussed 
by Raffa (2009), changes were evident at about two months then appeared to plateau at 
about six months and persisted for the duration of the study (which was about one year).  
 Staat and Segatore (2005) discussed three possible mechanisms that cause CB: 
direct neurotoxicity, inflammatory mechanisms, or a vascular mechanism. The theory of 
direct neurotoxicity implies that chemo agents cause direct toxicity to the brain, 
producing demyelination. The theory of an inflammatory response has to do with chemo 
agents destroying healthy cells in addition to cancer cells. This destruction of healthy 
cells produces a physiologic stress and the brain interprets the inflammatory response and 
the increase release of cytokines as stress, which may result in a decreased ability to 
learn, memory difficulties, and poor concentration (Evens & Eschiti, 2009).  The last 
theory involves a vascular mechanism where injury obstructs the microvasculature of the 
brain, causing ischemia or infarction of dependent brain tissue leading to the deficits of 
CB (Staat & Segatore, 2005).  
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Because cancer treatment is often multimodal, it is important to understand that 
both chemotherapy and radiation may be used. If this is the case, it makes it very difficult 
to separate the adverse effects (Raffa et al., 2006). According to Evens & Eschiti (2009), 
Cyclophosphamide and 5-fluorouracil are two of the most commonly used chemo drugs 
that can readily cross the BBB. Because of this, they are thought to significantly 
contribute to CB. Although chemo drugs such as methotrexate (MTX) and vincristine are 
not believed to penetrate the BBB, they are believed to play a role in altering its 
permeability, which allows the drugs to gain entry to the brain, also contributing to CB. 
According to Staat & Segatore (2005), cyclophosphamide, MTX, and fluorouracil in high 
doses are known to have the strongest association with the development of CB. As 
expected, more cognitive impairments were noted in patients who were given high doses 
of chemo compared to a standard dose, and more cognitive impairment was seen in 
patients given a standard dose of chemo than in control groups (Raffa et al., 2006). High 
dose chemotherapy, especially with MTX, has been associated with the previously 
discussed white matter injury (Mulhern & Palmer, 2003). 
There are many risk factors and contributing factors relating to CB. Both Duffner 
(2009) and Mulhern & Palmer (2003) discussed the finding that early age at diagnosis 
and chemotherapy treatment has consistently been identified as a major risk factor for 
developing CB. Mulhern & Palmer (2003) also discussed how being of female gender 
confers a greater risk for developing CB. They also stated that the factors of early age at 
diagnosis and start of chemo treatment along with low socioeconomic status were 
associated with more severe CB in females, but did not reliably correlate in males. It has 
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also been suggested that people who carry the APOE e4 gene (a gene associated with 
Alzheimer’s) may be more susceptible to CB (Evens & Eschiti, 2009).  
 
Assessment of Severity 
Deficits of CB may me subtle, so they may only be noticeable to the patient and 
family and not to the health care team. Evens & Eschiti (2009) provided the statistic that 
only 38% of nurses assessed patients for CB. While longitudinal evaluation of cognitive 
functioning for childhood cancer survivors is not yet considered standard of care, many 
pediatric oncology programs emphasize cognitive assessment for high-risk patients 
(Ullrich & Embry, 2012).  
Because there may be different contributing factors to the cognitive decline, there 
are differential diagnoses that must be ruled out in order to conclude that the deficits are 
caused by the chemotherapy (Evens & Eschiti, 2009). According to Staat & Segatore 
(2005), observational assessment is the most appropriate method to screen for CB.  
The neurocognitive assessments are essential in facilitating access to the 
necessary special education services and in tracking the child’s development over time. 
Ullrich & Embry (2012) suggested that a comprehensive neurocognitive assessment 
should focus on global intellectual functioning and academic achievement along with 
other specific high-risk areas of deficit. They also discussed the recommendation that 
high-risk survivors should be evaluated when they transition into a long-term follow-up 
program. This should be done both to detect subtle impacts on overall functioning and to 
serve as a baseline for future assessments since it is known that CB late effects can 
progress over time. This reevaluation should look at factors such as academic 
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performance, any acute changes or new difficulties, and the individual child’s specific 
risk factors.  
Ullrich & Embry (2012) also provided a table providing commonly used 
assessment tools for assessing specific neurocognitive domains in children. To assess 
global cognitive functioning (IQ), the WISC-IV is often used. The CPT-II or Trail 
Making Test Part A are often used to assess attention. The CMS may be used to assess 
memory. Processing speed may be assessed by the WISC-IV Coding/Symbol Search. 
Executive functioning may be assessed by a few tests, including the BRIEF or the Trail 
Making Test Part B. Finally, academic achievement may be assessed by the WIAT-III or 
WJ-III assessment tools.  
Practice Implications 
 According to Mulhern & Palmer (2003), interventions can be divided into 
two approaches: those that aim to avoid or reduce the neurotoxicity of the CNS 
therapy, and those that aim to minimize or rehabilitate deficits that are not 
preventable. First, in order to determine potential interventions, the cognitive 
deficits must be distinguished from brain metastases and other medical conditions 
(Evens & Eschiti, 2009). The earlier the deficits are recognized and attributed to 
chemotherapy treatment, the earlier potential treatments can begin.  
 One of the first implications of practice is education. Nurses play a significant 
role in educating patients and families about the diagnosis, treatments, and 
potential side effects. According to Staat & Segatore (2005), there is a huge debate 
about whether or not the risk of CB should be disclosed during the consent process. 
On one hand, when a treatment regimen has a known central neurotoxicity, it is 
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required to provide informed consent. On the other hand, there is limited 
knowledge regarding CB, and the incidence of CB must be confirmed before 
including it in routine discussion and as part of the informed consent process. 
Patients and families who have experienced CB first hand emphasized the desire for 
full disclosure or risks, including the potential for CB (Staat & Segatore, 2005). 
Education can allow patients to cope more effectively and the resulting awareness 
may be able to provide some sense of control and encourage the family to connect 
with an appropriate resource. As of 2009, there were no nationally known support 
groups for CB, so the pediatric oncology nurse should strongly consider finding a 
way to develop local groups (Evens & Eschiti, 2009).  
 Another intervention that is suggested to improve cognition during CB is 
exercise. Evens & Eschiti (2009) stated that because exercise improves blood flow 
and oxygenation to the brain, it might lead to improved cognitive functioning. They 
also stated that acupuncture has recently been shown to dilate cerebral blood 
vessels, which improves circulation as well as increases oxygenation to the brain.  
 When the non-pharmacological interventions are not sufficient, there are 
some proposed pharmacological interventions to minimize the deficits of CB. Both 
Ullrich & Embry (2012) and Staat & Segatore (2005) mentioned the use of 
methylphenidate (Ritalin) as an option to help with inattention, organizational 
skills, as well as forgetfulness. Both Evens & Eschiti (2009) and Staat & Segatore 
(2005) discussed the use of erythropoietin and epoetin alfa. These drugs are used to 
treat chemotherapy-induced anemia – they increase the oxygen carrying capacity of 
blood, which in turn can lead to decreased ischemia and hypoxia in the brain, 
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leading to cognitive improvement. Both sources also discuss the use of Gingko 
Biloba. This herb is thought to have a neuroprotective, antioxidant, and membrane-
stabilizing effect as well as possibly inhibiting the loss of cholinergic receptors, 
which are known to have an impact on memory and cognition (Staat & Segatore, 
2005).  
Theoretical Framework 
A theoretical framework that will guide the research is Erikson’s Theory of 
Psychosocial Development. In this theory, Erikson divides the “life cycle” into eight 
stages, and the focus of this project will be on the school-age stage of Industry versus 
Inferiority. During this stage children will either begin to develop a sense of pride in their 
accomplishments and abilities (industry) or will doubt their ability to be successful 
(inferiority). According to Erikson (1950), when a child develops a sense of industry, 
bringing “a productive situation to completion” is a goal that will gradually “supersede 
the whims and wishes of play”. Simply put, the child will feel great satisfaction from 
completing a task. Erikson also discusses the danger of this stage, feelings of inadequacy 
or inferiority. Erikson (1950) states that if a child “despairs of his tools and skills or of his 
status among his tool partners, her may be discouraged from identification with them”, 
which may pull him back and result in isolation. In summary, if a child feels inadequate 
and incompetent in what he does, he will start to pull back and considers himself 
“doomed to mediocrity or inadequacy” (Erikson, 1950).  
  In the research, it is suggested that there are treatment related cognitive changes 
that children experience both throughout treatment and long term. Cognitive changes 
have become some of the most common and challenging problems associated with the 
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CNS-directed treatment for certain forms of cancer (Moore et al., 2013). This can lead to 
increasing gaps in their skills and knowledge compared to that of their classmates. This 
gap can greatly impact their development of either industry or inferiority. Industry is 
developed when a child can be confident and feel accomplished for tasks they are 
completing, while inferiority can develop when a child feels they are unable to 
accomplish tasks or be successful. With the gap in knowledge and skill that may be 
present in these children who have undergone chemotherapy, there is a significantly 
higher chance of them developing a sense of inferiority rather than the preferred sense of 
industry. These children will notice they are unable to keep up and begin to doubt 
themselves and their ability to be successful, further isolating them from their classmates.  
Research Question 
Based on what was reviewed and learned form the literature review, this study will 
investigate the following questions: 
1. How is “Chemo Brain” (CB) defined by the pediatric oncology nurses who 
assess it? 
2. According to the pediatric oncology nurses, what is the best evaluation of the 
severity of CB? 
3. How do pediatric oncology nurses describe their best practices to teach/support 
patients and their families experiencing CB?  
4. In conclusion, what are the best educational practices to teach about CB for 
families under stress with a child with cancer? 
Methods 
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This is a qualitative/descriptive pilot study. In descriptive studies, there is no 
manipulation of variables, and the focus is describing a phenomenon. The use of a 
descriptive study design in this case is beneficial because for this is a pilot study this 
researcher is soliciting personal experiences and knowledge. Pilot study results will 
enable the researcher to determine if the instrument is valid for the proposed research 
questions. This design can help to discover specific variables to manipulate and include 
in future experimental research.  
Subjects 
Overall, the subjects of this study will be pediatric oncology registered nurses 
(RNs) practicing in hospitals throughout the state. A majority of the subjects will be 
members of the Bay Area/Northern California chapter of the Association of Pediatric 
Hematology/Oncology Nurses (BAHPON) who attend the chapter educational event on 
February 5, 2015. In addition to these nurses, other pediatric oncology RNs will be 
recruited as subjects for the study through snowballing.  
Sampling Procedure 
Primarily, convenience sampling will be used. Convenience sampling is a non-
probability sampling technique where the research subjects are selected because of their 
convenient accessibility and proximity to the researcher, such as access to members of 
the BAHPON.  With convenience sampling, the subjects are not representative of the 
entire population. Snowball sampling will also be used to obtain subjects for the study. 
Snowballing is also a non-probability sampling technique and may also be known as 
chain referral sampling. Researchers use this technique when the subjects may be hard to 
locate. Potential subjects are found through referral from existing subjects. In the case of 
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this study, snowballing is used to reach out to other pediatric oncology RNs that may not 
be members of BAHPON or may have not been in attendance at the meeting. The reason 
for non-probability sampling for this study is that childhood cancer is very rare and very 
few nurses select to work in this discipline.  See Appendix A for a copy of the consent 
letter.  
Sample Size 
For a small pilot study, the nursing research literature encourages approximately 
13-50 subjects or elements for each variable identified. The goal sample size for this 
study is 30 pediatric oncology RNs because the identified variables include assessment of 
presence and severity, and best practices for education. Purposeful sampling techniques 
will continue until the desired number of 30 is achieved or the date of March 1, 2015 
dictates the completion of data collection.  
Instruments 
Research will be gathered through a survey given to pediatric oncology nurses. 
This instrument begins by inquiring demographic information about the subjects. It then 
asks both open-ended questions that explore RN’s perceptions and practices related to CB 
and closed ended questions using a Likert scale. See Appendix B for a copy of the 
instrument.  
Reliability 
For this pilot study, the researcher is concentrating on the development of a valid 
instrument. When replicated, reliability will be tested using the techniques of 
Chronbach’s Alpha.  
Validity 
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Two advanced practice RNs in pediatric oncology will provide instrument 
construct and content validity. Construct validity is the extent to which inferences can be 
made from the operationalizations in the study to the theoretical constructs on which the 
operationalizations were based. Content validity refers to whether or not the items on the 
instrument truly test what the study is looking at, and that the instrument is representative 
of the research questions. 
Step-by-Step Procedures 
1. Receive IRB approval from the Dominican University of California Institutional 
Review Board.  
2. Contact the president of BAPHON and request for permission to attend the 
February 5, 2015 meeting to give a short presentation of the study aims, methods, 
and time frame.  
3. If allowed, attend BAPOHN meeting and hand out copies of instrument.  
4. Request contact information of BAPOHN members for sending out another round 
of surveys to increase the amount of responses returned to primary investigator.  
5. Contact and send out copies of the instrument to pediatric oncology nurses 
reached through snowballing.  
6. Continue to send out copies of the instrument to members of the BAPOHN and 
other pediatric oncology nurses.  
7. End collection of data on March 1, 2015.  
8. Review all collected data. 
9. Analyze the collected data.  
10. Look for common themes in the open-ended responses.  
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To Whom It May Concern: 
 
My name is Jennifer Tapping and I am a senior nursing student at Dominican 
University of California. I am currently working on my senior thesis research study. 
 
I would like to invite you to participate in a research study that will be conducted 
between December 2014 and March 2015, among pediatric oncology nurses. The 
project is titled, “Nurse’s Perceptions of Best Practices to Educate and Support 
Pediatric Patients and Their Families Experiencing “Chemo Brain:” A Pilot Study”
 
Background: With more advanced and more aggressive chemotherapy cancer treatment 
leading to higher survival rates, complications with quality of life are becoming more 
prominent, especially delayed cognitive processing, commonly known as
(CB). At diagnosis and throughout treatment, patients and families are routinely educated 
about the plan of care, but according to oncology nurses’ reports,
regarding the possibility of cognitive declines or deficits are left out.
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associated with central nervous system (
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Purpose: The purpose of this study is three fold: 1) to define and discuss the etiology of 
CB, 2) to discuss the best assessment and evaluation of severity of CB, and 3) to explore 
pediatric oncology nurses’ reports of best pr
supporting pediatric patients and their families experiencing CB. 
 
Procedures: Data will be collected through a two
researcher that has construct and content validity provided by t







 too often details 
  
CNS) directed treatment, such as intrathecal 
blastic leukemia (ALL) and brain tumors. The estimated 
 et al., 2013).  
actice implications for teaching and 
 
-page survey instrument created by the 







PEDIATRIC PATIENTS AND FAMILIES EXPERIENCING “CHEMO BRAIN” 
   
19
Risks: This research study has no potential risks.  
 
Benefits: By participating in this research, further exploration and understanding of the 
best education and support practices related to CB in pediatric patients and their families 
may be reached. This may benefit the future practical implications related to CB.  
 
Costs: There are no costs involved in this research study other than the time given 
completing the instrument.  
 
Payments: There will be no payments for participation in this study. 
 
Questions: If there are any questions about this study, the primary investigator, Jennifer 
Tapping, may be contacted by email at jennifer.tapping@students.dominican.edu. In 
addition, if there are concerns or any distress occurs as a result of this study, the research 
advisor, Dr. Luanne Linnard-Palmer, who is a practicing pediatric oncology nurse, may 
be contacted at (415)-257-1364 
 






























Nurse’s Perceptions of Best Practices to Educate and Support 












Years in Pediatric Hematology/Oncology_________________________________
 
Have you seen children with the neurological/central nervous system (CNS) to
signs of “Chemo Brain” (CB)? (Circle one)
 
   Yes 
 






How often do you see CB? (Circle one)
 
Never                Almost Never    
 








Pediatric Patients and 
Study 
   Age:___________________
________________________
 
    No 
______________________________
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How often do you include the possibility of CB in your treatment consent procedures? 
(Circle one) 
 
Never                Almost Never     Sometimes          Almost Always            Always 
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Thank you for your time! 
